InvestorsHub Logo
Post# of 252302
Next 10

BTH

Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: mcbio post# 179125

Tuesday, 06/10/2014 10:08:59 PM

Tuesday, June 10, 2014 10:08:59 PM

Post# of 252302
If you happened to listen to their last presentation, they are "evaluating" an expansion cohort in MM.....hardly an endorsement of efficacy.

So, now theyre stuck with DLBCL when other companies are now getting multiple CRs in early studies in this indication.

Move on to CUDC-427. Novartis testing their IAP in MM, MDS, lymphomas, ovarian, breast, MF. Curis decides to stick to MALT lymphomas as one heavy concentration along with ovarian. MALT lymphoma....an indication which can be cured early with antibiotics.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.